Shares of healthcare services company Astrana Health jumped 25.3% in the afternoon session after the company reported its fourth-quarter 2025 results, featuring strong revenue growth and a significant improvement in profitability.

The healthcare services company posted revenue of $950.5 million, a 42.9% increase year over year that beat Wall Street's estimates. Furthermore, Astrana reported a GAAP profit of $0.12 per share. While this was in line with analyst expectations, it represented a notable turnaround from a loss of $0.15 per share in the same quarter last year. This bottom-line improvement was supported by an expansion in its operating margin to 1.9% from 0.1% a year ago. Despite providing a mixed outlook, with revenue guidance for the next quarter meeting expectations but full-year EBITDA guidance falling slightly below, investors reacted positively to the strong quarterly performance.

Is now the time to buy Astrana Health? Access our full analysis report here, it’s free.

Astrana Health’s shares are very volatile and have had 29 moves greater than 5% over the last year. But moves this big are rare even for Astrana Health and indicate this news significantly impacted the market’s perception of the business.

The previous big move we wrote about was 17 days ago when the stock gained 3.8% on the news that a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve.

The January Consumer Price Index (CPI), a key measure of inflation, rose by 0.2%, which was less than economists had forecast, with the annual rate cooling to 2.4%. This encouraging data increased market expectations for the Fed to begin cutting interest rates as early as June. The news prompted a rally in Treasuries as their yields fell. While the market's reaction was initially described as a "bumpy ride" due to concerns in other sectors, the favorable inflation data ultimately helped calm Wall Street. Lower inflation is a key prerequisite for the central bank to ease its monetary policy, which is generally supportive of stock valuations.

Astrana Health is up 1.4% since the beginning of the year, but at $25.58 per share, it is still trading 24.9% below its 52-week high of $34.05 from April 2025. Investors who bought $1,000 worth of Astrana Health’s shares 5 years ago would now be looking at an investment worth $1,013.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.